Yahoo
    HKSE - Delayed Quote HKD

    InSilico Medicine Cayman TopCo (3696.HK)

    37.260 +1.260 (+3.50%)
    At close: 4:08:13 PM GMT+8
    Loading Chart for 3696.HK
    Chart Range Bar
    Interval:
    In partnership with ChartIQ

    Recent News

    View More
    Insilico Medicine Reports 40% ORR at 130 mg for Pan-TEAD Inhibitor ISM6331 Designed Using Generative AI in Heavily Pretreated Mesothelioma at ESMO 2026

    Insilico Medicine Reports 40% ORR at 130 mg for Pan-TEAD Inhibitor ISM6331 Designed Using Generative AI in Heavily Pretreated Mesothelioma at ESMO 2026
    PR Newswire 6d ago
    Global Longevity BioTech Market Size and Forecast Report 2026-2030 | Capitalize on 10.7% CAGR as Insilico Medicine, Calico, and Altos Labs Lead the Industry

    Global Longevity BioTech Market Size and Forecast Report 2026-2030 | Capitalize on 10.7% CAGR as Insilico Medicine, Calico, and Altos Labs Lead the Industry
    GlobeNewswire 12d ago
    AI-driven Molecular Glue Innovation: Insilico Nominates ISM9546, an Oral, Peripheral-Restricted VAV1 Degrader as PCC for Autoimmune Diseases

    AI-driven Molecular Glue Innovation: Insilico Nominates ISM9546, an Oral, Peripheral-Restricted VAV1 Degrader as PCC for Autoimmune Diseases
    PR Newswire 19d ago
    Breaking the Safety Barrier: Insilico Medicine Nominates ISM1354, the Next-Generation Small Molecule GIPR Antagonist

    Breaking the Safety Barrier: Insilico Medicine Nominates ISM1354, the Next-Generation Small Molecule GIPR Antagonist
    PR Newswire 1mo ago
    Capitalize on AI’s Drug Discovery Disruption: Benchmark NVIDIA, Schrödinger, Recursion, Insilico Medicine and Exscientia to Secure R&D ROI and Competitive Advantage Through 2030

    Capitalize on AI’s Drug Discovery Disruption: Benchmark NVIDIA, Schrödinger, Recursion, Insilico Medicine and Exscientia to Secure R&D ROI and Competitive Advantage Through 2030
    GlobeNewswire 1mo ago
    Insilico Medicine (SEHK:3696) Takes Its AI Discovered Drug Into Phase III Trials

    Insilico Medicine (SEHK:3696) Takes Its AI Discovered Drug Into Phase III Trials
    Simply Wall St. 1mo ago
    Insilico Medicine’s Alex Zhavoronkov bets China and AI can deliver the drug industry’s next breakthrough

    Insilico Medicine’s Alex Zhavoronkov bets China and AI can deliver the drug industry’s next breakthrough
    Fortune 1mo ago
    Insilico Medicine Doses First Patient in GENESIS-IPF-3, the World's First Phase III Trial of a Generative AI-Driven Innovative Drug

    Insilico Medicine Doses First Patient in GENESIS-IPF-3, the World's First Phase III Trial of a Generative AI-Driven Innovative Drug
    PR Newswire 1mo ago
    Artificial Intelligence (AI) for De Novo Drug Design Global Market Report 2026 | Secure 33.7% CAGR Through 2030 with Schrödinger, XtalPi, Owkin, Insilico Medicine and Recursion

    Artificial Intelligence (AI) for De Novo Drug Design Global Market Report 2026 | Secure 33.7% CAGR Through 2030 with Schrödinger, XtalPi, Owkin, Insilico Medicine and Recursion
    GlobeNewswire 5d ago
    In-Silico Drug Discovery Market Report Now Available: Capitalize on AI-led R&D disruption as revenue surges from $3.3B to $6B by 2030; benchmark Certara, Insilico Medicine, Isomorphic Labs, Exscientia and BenevolentAI to secure share.

    In-Silico Drug Discovery Market Report Now Available: Capitalize on AI-led R&D disruption as revenue surges from $3.3B to $6B by 2030; benchmark Certara, Insilico Medicine, Isomorphic Labs, Exscientia and BenevolentAI to secure share.
    GlobeNewswire 1mo ago
    Insilico Medicine Opens AI Longevity Discovery Toolkit to Researchers Worldwide in Cell Cover Study

    Insilico Medicine Opens AI Longevity Discovery Toolkit to Researchers Worldwide in Cell Cover Study
    PR Newswire 1mo ago
    View More

    Related Tickers

    Mobilize your Website
    View Site in Mobile | Classic
    Share by: